

Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Phone: Patient ID:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
------------------	-----------------	---------------------	------------------------	------------

LYME DISEASE AB W/REFL				TXC
------------------------	--	--	--	-----

TO BLOT (IGG, IGM)

LYME AB SCREEN

< or = 0.90

index

REFERENCE RANGE: <=0.90

INTERPRETIVE CRITERIA:

<= 0.90 NEGATIVE

0.91-1.09 EQUIVOCAL

>= 1.10 POSITIVE

The use of purified VlsE-1 and PepC10 antigens in this assay provides improved specificity compared to assays that utilize whole cell lysates of B. burgdorferi, the causative agent of Lyme disease, and slightly better sensitivity compared to the C6 antibody assay.

As recommended by the Food and Drug Administration (FDA), all samples with positive or equivocal results in a Borrelia burgdorferi antibody EIA (screening) will be tested using a blot method. Positive or equivocal screening test results should not be interpreted as truly positive until verified as such using a supplemental assay (e.g., B. burgdorferi blot).

The screening test and/or blot for B. burgdorferi antibodies may be falsely negative in early stages of Lyme disease, including the period when erythema migrans is apparent.